The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource




Ouellet Veronique, Erickson Andrew on behalf of GAP1 UTMAs Contributing Investigators, Wiley Kathy, Morrissey Colm, Berge Viktor, Moreno Carlos S., Tasken Kristin Austlid, Trudel Dominique, True Lawrence D., Lewis Michael S., Svindland Aud, Ertunc Onur, Vidal Igor Damasceno, Osunkoya Adeboye O., Jones Tracy, Bova G. Steven, Lamminen Tarja, Achtman Ariel H., Buzza Mark, Kouspou Michelle M., Bigler Steven A., Zhou Xinchun, Freedland Stephen J., Mes-Masson Anne-Marie, Garraway Isla P., Trock Bruce J., Taimen Pekka, Saad Fred, Mirtti Tuomas, Knudsen Beatrice S., De Marzo Angelo M.

PublisherAmerican Association for Cancer Research Inc.

2022

Cancer Epidemiology, Biomarkers and Prevention

Cancer Epidemiology Biomarkers and Prevention

31

4

715

727

1538-7755

DOIhttps://doi.org/10.1158/1055-9965.EPI-21-0600

https://doi.org/10.1158/1055-9965.EPI-21-0600

https://research.utu.fi/converis/portal/detail/Publication/175234626



Background

The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations.

Methods

Three separate TMA sets were built that differ by purpose and disease state.

Results

The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases.

Conclusions

The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation.

Impact

This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.


Last updated on 2024-26-11 at 11:33